Sangamo Therapeutics, Inc. SGMO was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 20.3% in the past one-month time frame.
The company's Zacks Consensus Estimate for the current quarter has moved higher over the past few weeks, suggesting that more solid trading could be ahead for Sangamo Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Sangamo Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Sangamo Therapeutics, Inc. Price
Sangamo Therapeutics, Inc. price | Sangamo Therapeutics, Inc. Quote
Investors interested in the Medical – Biomedical and Genetics industry may consider Alkermes plc ALKS, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is SGMO going up? Or down? Predict to see what others think:Up or Down
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS) : Free Stock Analysis Report
Sangamo Therapeutics, Inc. (SGMO) : Free Stock Analysis Report
To read this article on Zacks.com click here.